Does the media refer more to DTIL or PHAT?

In the previous week, Phathom Pharmaceuticals had 2 more articles in the media than Precision BioSciences. MarketBeat recorded 4 mentions for Phathom Pharmaceuticals and 2 mentions for Precision BioSciences. Precision BioSciences' average media sentiment score of 1.89 beat Phathom Pharmaceuticals' score of 0.58 indicating that Precision BioSciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Precision BioSciences 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Phathom Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor TBPH or DTIL?

In the previous week, Theravance Biopharma and Theravance Biopharma both had 2 articles in the media. Precision BioSciences' average media sentiment score of 1.89 beat Theravance Biopharma's score of 1.45 indicating that Precision BioSciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Theravance Biopharma 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Precision BioSciences 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Does the media refer more to DTIL or DSGN?

In the previous week, Precision BioSciences and Precision BioSciences both had 2 articles in the media. Precision BioSciences' average media sentiment score of 1.89 beat Design Therapeutics' score of 0.97 indicating that Precision BioSciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Precision BioSciences 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Design Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor DTIL or AMPH?

In the previous week, Amphastar Pharmaceuticals had 4 more articles in the media than Precision BioSciences. MarketBeat recorded 6 mentions for Amphastar Pharmaceuticals and 2 mentions for Precision BioSciences. Precision BioSciences' average media sentiment score of 1.89 beat Amphastar Pharmaceuticals' score of 1.08 indicating that Precision BioSciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Precision BioSciences 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Amphastar Pharmaceuticals 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to DTIL or REPL?

In the previous week, Replimune Group had 1 more articles in the media than Precision BioSciences. MarketBeat recorded 3 mentions for Replimune Group and 2 mentions for Precision BioSciences. Precision BioSciences' average media sentiment score of 1.89 beat Replimune Group's score of 0.95 indicating that Precision BioSciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Precision BioSciences 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Replimune Group 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Precision BioSciences (DTIL) Competitors

$7.29 -0.04 (-0.55%)

Closing price 07/24/2026 04:00 PM Eastern

Extended Trading

$7.26 -0.03 (-0.34%)

As of 07/24/2026 07:34 PM Eastern

Compare

DTIL vs. PHAT, TBPH, DSGN, AMPH, and REPL

Should you buy Precision BioSciences stock or one of its competitors? MarketBeat compares Precision BioSciences with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Precision BioSciences include Phathom Pharmaceuticals (PHAT), Theravance Biopharma (TBPH), Design Therapeutics (DSGN), Amphastar Pharmaceuticals (AMPH), and Replimune Group (REPL). These companies are all part of the "pharmaceutical products" industry.

How does Precision BioSciences compare to Phathom Pharmaceuticals?

Precision BioSciences (NASDAQ:DTIL) and Phathom Pharmaceuticals (NASDAQ:PHAT) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, valuation, risk, profitability, dividends, earnings, analyst recommendations and media sentiment.

Precision BioSciences has a beta of 1.25, meaning that its stock price is 25% more volatile than the broader market. Comparatively, Phathom Pharmaceuticals has a beta of 0.49, meaning that its stock price is 51% less volatile than the broader market.

In the previous week, Phathom Pharmaceuticals had 2 more articles in the media than Precision BioSciences. MarketBeat recorded 4 mentions for Phathom Pharmaceuticals and 2 mentions for Precision BioSciences. Precision BioSciences' average media sentiment score of 1.89 beat Phathom Pharmaceuticals' score of 0.58 indicating that Precision BioSciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Precision BioSciences	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Phathom Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Phathom Pharmaceuticals has a net margin of -76.77% compared to Precision BioSciences' net margin of -96.73%. Phathom Pharmaceuticals' return on equity of 0.00% beat Precision BioSciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Precision BioSciences	-96.73%	-85.37%	-37.34%
Phathom Pharmaceuticals	-76.77%	N/A	-44.29%

Precision BioSciences has higher earnings, but lower revenue than Phathom Pharmaceuticals. Phathom Pharmaceuticals is trading at a lower price-to-earnings ratio than Precision BioSciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Precision BioSciences	$45.07M	4.17	-$45.72M	-$3.67	N/A
Phathom Pharmaceuticals	$204.89M	4.45	-$221.25M	-$2.12	N/A

Precision BioSciences currently has a consensus target price of $32.25, indicating a potential upside of 342.39%. Phathom Pharmaceuticals has a consensus target price of $24.50, indicating a potential upside of 114.16%. Given Precision BioSciences' higher probable upside, research analysts clearly believe Precision BioSciences is more favorable than Phathom Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Precision BioSciences	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60
Phathom Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86

38.0% of Precision BioSciences shares are owned by institutional investors. Comparatively, 99.0% of Phathom Pharmaceuticals shares are owned by institutional investors. 2.7% of Precision BioSciences shares are owned by insiders. Comparatively, 9.3% of Phathom Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Summary

Phathom Pharmaceuticals beats Precision BioSciences on 11 of the 17 factors compared between the two stocks.

How does Precision BioSciences compare to Theravance Biopharma?

Theravance Biopharma (NASDAQ:TBPH) and Precision BioSciences (NASDAQ:DTIL) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, valuation, media sentiment, profitability, risk, dividends, earnings and institutional ownership.

Theravance Biopharma presently has a consensus price target of $19.40, indicating a potential upside of 15.07%. Precision BioSciences has a consensus price target of $32.25, indicating a potential upside of 342.39%. Given Precision BioSciences' stronger consensus rating and higher probable upside, analysts plainly believe Precision BioSciences is more favorable than Theravance Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Theravance Biopharma	0 Sell rating(s)	8 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
Precision BioSciences	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60

Theravance Biopharma has higher revenue and earnings than Precision BioSciences. Precision BioSciences is trading at a lower price-to-earnings ratio than Theravance Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Theravance Biopharma	$107.46M	8.09	$105.89M	$2.20	7.66
Precision BioSciences	$45.07M	4.17	-$45.72M	-$3.67	N/A

99.1% of Theravance Biopharma shares are owned by institutional investors. Comparatively, 38.0% of Precision BioSciences shares are owned by institutional investors. 7.7% of Theravance Biopharma shares are owned by company insiders. Comparatively, 2.7% of Precision BioSciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

In the previous week, Theravance Biopharma and Theravance Biopharma both had 2 articles in the media. Precision BioSciences' average media sentiment score of 1.89 beat Theravance Biopharma's score of 1.45 indicating that Precision BioSciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Theravance Biopharma	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Precision BioSciences	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Theravance Biopharma has a beta of 0.17, suggesting that its stock price is 83% less volatile than the broader market. Comparatively, Precision BioSciences has a beta of 1.25, suggesting that its stock price is 25% more volatile than the broader market.

Theravance Biopharma has a net margin of 104.34% compared to Precision BioSciences' net margin of -96.73%. Theravance Biopharma's return on equity of 18.84% beat Precision BioSciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Theravance Biopharma	104.34%	18.84%	10.94%
Precision BioSciences	-96.73%	-85.37%	-37.34%

Summary

Theravance Biopharma beats Precision BioSciences on 10 of the 15 factors compared between the two stocks.

How does Precision BioSciences compare to Design Therapeutics?

Precision BioSciences (NASDAQ:DTIL) and Design Therapeutics (NASDAQ:DSGN) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, media sentiment, valuation, institutional ownership, analyst recommendations, profitability, dividends and earnings.

38.0% of Precision BioSciences shares are held by institutional investors. Comparatively, 56.6% of Design Therapeutics shares are held by institutional investors. 2.7% of Precision BioSciences shares are held by company insiders. Comparatively, 17.1% of Design Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Precision BioSciences presently has a consensus target price of $32.25, suggesting a potential upside of 342.39%. Design Therapeutics has a consensus target price of $16.50, suggesting a potential upside of 40.07%. Given Precision BioSciences' higher probable upside, equities research analysts clearly believe Precision BioSciences is more favorable than Design Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Precision BioSciences	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60
Design Therapeutics	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88

Precision BioSciences has higher revenue and earnings than Design Therapeutics. Design Therapeutics is trading at a lower price-to-earnings ratio than Precision BioSciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Precision BioSciences	$45.07M	4.17	-$45.72M	-$3.67	N/A
Design Therapeutics	N/A	N/A	-$69.79M	-$1.20	N/A

In the previous week, Precision BioSciences and Precision BioSciences both had 2 articles in the media. Precision BioSciences' average media sentiment score of 1.89 beat Design Therapeutics' score of 0.97 indicating that Precision BioSciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Precision BioSciences	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Design Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Design Therapeutics has a net margin of 0.00% compared to Precision BioSciences' net margin of -96.73%. Design Therapeutics' return on equity of -33.07% beat Precision BioSciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Precision BioSciences	-96.73%	-85.37%	-37.34%
Design Therapeutics	N/A	-33.07%	-31.29%

Precision BioSciences has a beta of 1.25, suggesting that its share price is 25% more volatile than the broader market. Comparatively, Design Therapeutics has a beta of 1.58, suggesting that its share price is 58% more volatile than the broader market.

Summary

Design Therapeutics beats Precision BioSciences on 10 of the 15 factors compared between the two stocks.

How does Precision BioSciences compare to Amphastar Pharmaceuticals?

Precision BioSciences (NASDAQ:DTIL) and Amphastar Pharmaceuticals (NASDAQ:AMPH) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, earnings, profitability, institutional ownership, media sentiment, valuation and risk.

Amphastar Pharmaceuticals has higher revenue and earnings than Precision BioSciences. Precision BioSciences is trading at a lower price-to-earnings ratio than Amphastar Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Precision BioSciences	$45.07M	4.17	-$45.72M	-$3.67	N/A
Amphastar Pharmaceuticals	$719.89M	1.15	$98.09M	$1.66	11.28

In the previous week, Amphastar Pharmaceuticals had 4 more articles in the media than Precision BioSciences. MarketBeat recorded 6 mentions for Amphastar Pharmaceuticals and 2 mentions for Precision BioSciences. Precision BioSciences' average media sentiment score of 1.89 beat Amphastar Pharmaceuticals' score of 1.08 indicating that Precision BioSciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Precision BioSciences	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Amphastar Pharmaceuticals	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

38.0% of Precision BioSciences shares are held by institutional investors. Comparatively, 65.1% of Amphastar Pharmaceuticals shares are held by institutional investors. 2.7% of Precision BioSciences shares are held by insiders. Comparatively, 29.6% of Amphastar Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Precision BioSciences has a beta of 1.25, suggesting that its share price is 25% more volatile than the broader market. Comparatively, Amphastar Pharmaceuticals has a beta of 0.89, suggesting that its share price is 11% less volatile than the broader market.

Amphastar Pharmaceuticals has a net margin of 11.00% compared to Precision BioSciences' net margin of -96.73%. Amphastar Pharmaceuticals' return on equity of 15.12% beat Precision BioSciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Precision BioSciences	-96.73%	-85.37%	-37.34%
Amphastar Pharmaceuticals	11.00%	15.12%	7.14%

Precision BioSciences presently has a consensus target price of $32.25, suggesting a potential upside of 342.39%. Amphastar Pharmaceuticals has a consensus target price of $22.00, suggesting a potential upside of 17.52%. Given Precision BioSciences' stronger consensus rating and higher possible upside, research analysts clearly believe Precision BioSciences is more favorable than Amphastar Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Precision BioSciences	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60
Amphastar Pharmaceuticals	2 Sell rating(s)	6 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.75

Summary

Amphastar Pharmaceuticals beats Precision BioSciences on 10 of the 16 factors compared between the two stocks.

How does Precision BioSciences compare to Replimune Group?

Precision BioSciences (NASDAQ:DTIL) and Replimune Group (NASDAQ:REPL) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, valuation, earnings, media sentiment, analyst recommendations and risk.

Precision BioSciences has a beta of 1.25, meaning that its share price is 25% more volatile than the broader market. Comparatively, Replimune Group has a beta of 0.86, meaning that its share price is 14% less volatile than the broader market.

Precision BioSciences has higher revenue and earnings than Replimune Group. Replimune Group is trading at a lower price-to-earnings ratio than Precision BioSciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Precision BioSciences	$45.07M	4.17	-$45.72M	-$3.67	N/A
Replimune Group	N/A	N/A	-$313.94M	-$3.38	N/A

In the previous week, Replimune Group had 1 more articles in the media than Precision BioSciences. MarketBeat recorded 3 mentions for Replimune Group and 2 mentions for Precision BioSciences. Precision BioSciences' average media sentiment score of 1.89 beat Replimune Group's score of 0.95 indicating that Precision BioSciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Precision BioSciences	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Replimune Group	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Precision BioSciences presently has a consensus price target of $32.25, indicating a potential upside of 342.39%. Replimune Group has a consensus price target of $8.86, indicating a potential downside of 8.69%. Given Precision BioSciences' stronger consensus rating and higher possible upside, equities analysts plainly believe Precision BioSciences is more favorable than Replimune Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Precision BioSciences	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60
Replimune Group	2 Sell rating(s)	5 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.00

38.0% of Precision BioSciences shares are held by institutional investors. Comparatively, 92.5% of Replimune Group shares are held by institutional investors. 2.7% of Precision BioSciences shares are held by company insiders. Comparatively, 5.2% of Replimune Group shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Replimune Group has a net margin of 0.00% compared to Precision BioSciences' net margin of -96.73%. Precision BioSciences' return on equity of -85.37% beat Replimune Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Precision BioSciences	-96.73%	-85.37%	-37.34%
Replimune Group	N/A	-128.57%	-82.35%

Summary

Precision BioSciences beats Replimune Group on 10 of the 15 factors compared between the two stocks.

Get Precision BioSciences News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding DTIL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

DTIL vs. The Competition

Export

Metric	Precision BioSciences	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$189.13M	$3.67B	$6.88B	$12.25B
Dividend Yield	N/A	2.19%	2.67%	9.79%
P/E Ratio	-1.99	21.11	27.00	23.71
Price / Sales	4.17	163.85	492.30	74.42
Price / Cash	N/A	157.90	50.54	59.64
Price / Book	1.81	7.88	10.28	6.07
Net Income	-$45.72M	$23.81M	$3.60B	$331.99M
7 Day Performance	-7.37%	-3.82%	-1.29%	-0.61%
1 Month Performance	8.00%	-2.61%	-0.38%	-1.98%
1 Year Performance	41.55%	32.79%	18.32%	13.67%

Precision BioSciences Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
DTIL Precision BioSciences	2.7126 of 5 stars	$7.29 -0.5%	$32.25 +342.4%	+45.8%	$189.13M	$45.07M	N/A	200	News Coverage Positive News
PHAT Phathom Pharmaceuticals	2.2524 of 5 stars	$11.04 +1.2%	$24.50 +121.9%	+26.4%	$880.55M	$175.11M	N/A	110	News Coverage Upcoming Earnings
TBPH Theravance Biopharma	2.943 of 5 stars	$16.92 +0.1%	$19.40 +14.7%	+51.5%	$872.23M	$107.46M	7.69	110	Positive News
DSGN Design Therapeutics	2.4925 of 5 stars	$13.67 -1.3%	$16.50 +20.7%	+191.6%	$853.83M	N/A	N/A	40	Gap Down
AMPH Amphastar Pharmaceuticals	3.6073 of 5 stars	$18.81 -2.5%	$22.00 +17.0%	-16.8%	$829.33M	$719.89M	11.33	1,976	Analyst Upgrade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:DTIL) was last updated on 7/25/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Precision BioSciences (DTIL) Competitors

DTIL vs. PHAT, TBPH, DSGN, AMPH, and REPL

How does Precision BioSciences compare to Phathom Pharmaceuticals?

Summary

How does Precision BioSciences compare to Theravance Biopharma?

Summary

How does Precision BioSciences compare to Design Therapeutics?

Summary

How does Precision BioSciences compare to Amphastar Pharmaceuticals?

Summary

How does Precision BioSciences compare to Replimune Group?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

DTIL vs. The Competition

Precision BioSciences Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Precision BioSciences (DTIL) Competitors

DTIL vs. PHAT, TBPH, DSGN, AMPH, and REPL

How does Precision BioSciences compare to Phathom Pharmaceuticals?

Which has more risk & volatility, DTIL or PHAT?

Does the media refer more to DTIL or PHAT?

Is DTIL or PHAT more profitable?

Which has stronger earnings and valuation, DTIL or PHAT?

Do analysts recommend DTIL or PHAT?

Do insiders and institutionals believe in DTIL or PHAT?

Summary

How does Precision BioSciences compare to Theravance Biopharma?

Do analysts prefer TBPH or DTIL?

Which has stronger valuation & earnings, TBPH or DTIL?

Do institutionals and insiders have more ownership in TBPH or DTIL?

Does the media favor TBPH or DTIL?

Which has more risk and volatility, TBPH or DTIL?

Is TBPH or DTIL more profitable?

Summary

How does Precision BioSciences compare to Design Therapeutics?

Do insiders & institutionals believe in DTIL or DSGN?

Do analysts prefer DTIL or DSGN?

Which has better earnings & valuation, DTIL or DSGN?

Does the media refer more to DTIL or DSGN?

Is DTIL or DSGN more profitable?

Which has more risk & volatility, DTIL or DSGN?

Summary

How does Precision BioSciences compare to Amphastar Pharmaceuticals?

Which has stronger earnings and valuation, DTIL or AMPH?

Does the media favor DTIL or AMPH?

Do insiders & institutionals hold more shares of DTIL or AMPH?

Which has more volatility & risk, DTIL or AMPH?

Is DTIL or AMPH more profitable?

Do analysts prefer DTIL or AMPH?

Summary

How does Precision BioSciences compare to Replimune Group?

Which has more volatility & risk, DTIL or REPL?

Which has preferable valuation and earnings, DTIL or REPL?

Does the media refer more to DTIL or REPL?

Do analysts prefer DTIL or REPL?

Do insiders & institutionals believe in DTIL or REPL?

Is DTIL or REPL more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

DTIL vs. The Competition

Precision BioSciences Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools